CLYM

Climb Bio, Inc. Common Stock

1.95 USD
+0.00
0.00%
At close Dec 20, 4:00 PM EST
After hours
1.95
+0.00
0.00%
1 day
0.00%
5 days
-25.86%
1 month
-36.69%
3 months
-62.21%
6 months
-62.21%
Year to date
-62.21%
1 year
-62.21%
5 years
-62.21%
10 years
-62.21%
 

About: Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.

Employees: 11

0
Funds holding %
of 6,809 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

300% more first-time investments, than exits

New positions opened: 32 | Existing positions closed: 8

286% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 7

51% more funds holding

Funds holding: 47 [Q2] → 71 (+24) [Q3]

22% less capital invested

Capital invested by funds: $355M [Q2] → $278M (-$76.7M) [Q3]

50% less funds holding in top 10

Funds holding in top 10: 2 [Q2] → 1 (-1) [Q3]

Research analyst outlook

We haven’t received any recent analyst ratings for CLYM.

Financial journalist opinion

Neutral
GlobeNewsWire
3 days ago
Climb Bio to be Added to the Nasdaq Biotechnology Index
WELLESLEY HILLS, Mass., Dec. 19, 2024 (GLOBE NEWSWIRE) -- December 19, 2024 – Climb Bio, Inc. (Nasdaq: CLYM) today announced that the company will be added to the NASDAQ Biotech Index (Nasdaq: NBI) as part of the annual reconstitution of the 2024 Nasdaq indexes. Climb Bio's inclusion in the Nasdaq Biotechnology Index will be effective prior to market open on Monday, December 23, 2024.
Climb Bio to be Added to the Nasdaq Biotechnology Index
Neutral
GlobeNewsWire
1 month ago
Climb Bio Reports Third Quarter 2024 Financial Results and Business Highlights
Appointed Douglas Williams, Ph.D. as Chair of the Board of Directors FDA Clearance of Investigational New Drug Application (IND) for systemic lupus erythematosus (SLE) Expanded Management Team with the Appointment of Gary Hao, Ph.D.
Climb Bio Reports Third Quarter 2024 Financial Results and Business Highlights
Neutral
GlobeNewsWire
1 month ago
Climb Bio Appoints Douglas E. Williams, Ph.D.
WELLESLEY, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) today announced the appointment of Douglas E. Williams, Ph.D., as Climb Bio's Chair of its Board of Directors. Dr. Williams will assume the role of Chair of the Board, succeeding Andrew Levin, who will remain on the Board as a director, while Liam Ratcliffe will step down from his position as a director. Dr. Williams has over 30 years of executive leadership experience in the biotechnology sector. Throughout his career, Dr. Williams has held leadership roles in research and development, contributing significantly to the creation of drugs such as Leukine®, Enbrel®, Adcetris®, Tecfidera®, Alprolix®, Eloctate® and Spinraza®. As a CEO, he has successfully guided both private and public companies from development to commercialization and has overseen multiple successful mergers.
Climb Bio Appoints Douglas E. Williams, Ph.D.
Neutral
GlobeNewsWire
2 months ago
Climb Bio to Provide Budoprutug Development Strategy and Corporate Update at Virtual Investor Event
Completes Transition to Immune-Mediated Disease Focused Company Highlights Additional Data from Phase 1b Primary Membranous Nephropathy (pMN) Study with plans to Advance to Late Phase Development in 2025 Outlines Plans for Clinical Trial s in Systemic Lupus Erythematosus (SLE) and Immune Thrombocytopenia (ITP) with First Patients Dosed Targeted for 1H25 Cash runway through 2027 Expected to Enable Delivery of Key Value Inflection Points Virtual Investor Event to be Held at 12:00 p.m. ET Today WELLESLEY HILLS, Mass.
Climb Bio to Provide Budoprutug Development Strategy and Corporate Update at Virtual Investor Event
Neutral
GlobeNewsWire
2 months ago
Climb Bio Announces Abstract Selected for Presentation at the American Society of Nephrology Kidney Week 2024
WELLESLEY, Mass., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), announced that it will present data at the American Society of Nephrology Kidney Week 2024, which will take place in San Diego, CA from October 23-27, 2024.
Climb Bio Announces Abstract Selected for Presentation at the American Society of Nephrology Kidney Week 2024
Neutral
GlobeNewsWire
2 months ago
Climb Bio to Present at William Blair's Upcoming Conference Event on Transforming Autoimmune Diseases by Targeting CD19
WELLESLEY, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), announced today it will present and host investor meetings at William Blair's Transforming Autoimmune Diseases by Targeting CD19 event being held in New York, NY on Wednesday, October 16, 2024.
Climb Bio to Present at William Blair's Upcoming Conference Event on Transforming Autoimmune Diseases by Targeting CD19
Neutral
GlobeNewsWire
2 months ago
Climb Bio to Host Virtual Investor Event on October 15, 2024
WELLESLEY, Mass., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), announced today it will host a virtual investor day on October 15, 2024. The event will feature members of Climb Bio's management team and an external expert who will provide an update to the investment community on the Company's strategy and focus on developing therapeutics for immune-mediated diseases.
Climb Bio to Host Virtual Investor Event on October 15, 2024
Charts implemented using Lightweight Charts™